Drugs / G17DT Immunogen
G17DT Immunogen
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 211 trials | ||||||
| Phase 2 | NCT02118064 | Mar 2001 → Dec 2002 | colorectal cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02518529 | Feb 2001 → Dec 2002 | gastric cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00042510 | Aug 2000 → Feb 2003 | gastric neoplasm, neoplasm of esophagus | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02223078 | Jul 2000 → Aug 2001 | colorectal cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02518373 | Apr 2000 → Feb 2001 | colorectal cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02450032 | Feb 2000 → May 2001 | gastric cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02233712 | Aug 1999 → Mar 2000 | gastric cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02098291 | Apr 1999 → Jul 2001 | malignant pancreatic neoplasm | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02521649 | Sep 1998 → Jan 2001 | gastric cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02228785 | May → Oct 1994 | colorectal cancer | Cancer Advances Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02181465 | Oct 1993 → May 1994 | colorectal cancer | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00020787 | Jul 2001 → Jan 2002 | esophageal cancer, gastric cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02118077 | Apr 2001 → Apr 2004 | malignant pancreatic neoplasm | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00044031 | Feb 2001 → Apr 2004 | malignant pancreatic neoplasm | Cancer Advances Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03200821 | Aug 2000 → Sep 2001 | malignant pancreatic neoplasm | Cancer Advances Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02098239 Comparator | Aug 1999 → Apr 2002 | hyperbilirubinemia, malignant pancreatic neoplasm | Cancer Advances Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G17DT Immunogen | “Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer” NCT00042510 ↗ |
| Known as | G17DT | “Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer” NCT00042510 ↗ |
| Known as | G17dt (an antigastrin immunogen) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095277 ↗ |
| Known as | Gastrimmune | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095277 ↗ |
| Action | Inhibit | “thus preventing the trophic activity of cancer cells.” NCT02181465 ↗ |
| Modality | Vaccine | “G17DT vaccination” PMID 16568451 ↗ May 2006 |
| Route | Intramuscular | “Route: Deep intramuscular” NCT00020787 ↗ |